In 2025, Medicare Part D caps oral cancer drug out-of-pocket costs at $2,000, introducing a monthly payment plan to aid affordability and adherence for beneficiaries.

The 2024 cancer report highlights declines in US cancer mortality through 2022, with 2020 pandemic-related diagnosis drops not persisting into 2021. Key insights for oncology insurers and providers.